Nature Biotechnology | Trade Secrets

The News Net

news net2Your weekend reading includes the hunt for Europe’s most innovative biotech, food for thought about investment into IT, continued good news for some of the BRICs and what’s new in agbiotech.
 
 
  • EuropaBio has put out its call for applications for the 4th annual Most Innovative European Biotech SME Award 2013, with a €10,000 cash prize and free membership of EuropaBio on the line. Applications forms can be downloaded from EuropaBio’s website until the deadline of June 10th.
  • For most biotech start-ups, experimental data is their most valuable asset, and constitutes the bulk of their intellectual property. Companies not equipped to store, protect and access the data are at risk, so blog Business 2 Community lays out four reasons why biotech startups must think carefully about their IT investment.
  • The Indian biotech sector looks to be a good bet, according to Greater Manchester’s investment agency MIDAS. On the heels of the just-launched Manchester-China Forum, a business-led initiative aimed at increasing Greater Manchester’s commercial connectivity with China, MIDAS CEO Tim Newns said the agency will be focusing on India and the biotech sector as key targets in 2013. Read the details here.
  • Taiwan’s biotech sector will continue to expand, according to a report in The China Post. Investment in the sector rose 18.66 percent year-on-year in 2012 to NT$39.53 billion, with sales rising 6.1 percent to NT$255 billion. More here.
  • Turning to agbiotech, Monsanto Pakistan briefed a delegation of journalists and hosted a tour of its state-of-the-art research center inManga Mandi, where field trials of its GM corn product “VT Double Pro” and various vegetables and fruits are ongoing. Company officials said that Pakistan can address challenges in agriculture by embracing biotech, as globally theadoption of GM crops has been a success with proven socio-economic benefits.
  • Finally, VC firm Kapyon Ventures announced that two of the agbiotech companies it has incubated have raised $5.8 million. Algenetix and ZeaKal are developing microbial and plant technologies under the “virtual biotech” model now popular in the industry. The complete article is here.

Comments

There are currently no comments.